Changes in platelet levels after eltrombopag/eltrombopag discontinuation

Eltrombopag/Eltrombopag, as an innovative drug, has been widely used to treat thrombocytopenia caused by idiopathic thrombocytopenic purpura (ITP) in adults. As a thrombopoietin receptor agonist, it can effectively stimulate bone marrow cells and promote platelet production.

When patients take eltrombopag daily, they can choose to take it in pill or liquid form, taking it regularly once a day. Regarding the way of taking the medicine, it is recommended that patients take it on an empty stomach or with food low in calcium to ensure the best absorption of the medicine. At the same time, patients should avoid crushing, chewing, or breaking tablets to maintain the integrity and effectiveness of the medication. If the patient chooses the liquid form of the drug, dosage preparation instructions should be followed strictly.

Observations from some clinical trials have shown that some patients' platelet counts will decrease after stopping taking eltrombopag, even lower than before taking the drug. This side effect usually occurs soon after stopping the medication and may last for about a month. This emphasizes the importance of eltrombopag as a long-term treatment. If the patient stops taking the medication or misses the dose without following medical advice, he or she may be at risk of a decrease in platelet count. When platelet levels drop dangerously low, serious consequences such as bleeding can occur. Therefore, patients should pay close attention to changes in their platelet levels and promptly report any abnormal symptoms, such as bruising or bleeding, to their doctor.

Patients of East Asian ancestry or with liver problems should use eltrombopag with particular caution. Due to the potential risk of hepatotoxicity, treatment in these patients is often initiated at a lower dose. At the same time, regular laboratory tests are essential to monitor changes in patients' blood cell counts and liver function. It should be emphasized that eltrombopag is only indicated for the treatment of thrombocytopenia caused byITP, hepatitis C, or aplastic anemia. Eltrombopag is not suitable for conditions such as low platelet counts caused by other diseases or myelodysplastic syndrome (pre-leukemia).